{"id":828551,"date":"2026-08-04T01:41:02","date_gmt":"2026-08-04T01:41:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=828551"},"modified":"2026-08-04T01:41:02","modified_gmt":"2026-08-04T01:41:02","slug":"ibogaine-by-david-dardashti-unveils-minimalist-jungian-paradigm-for-early-trauma-appoints-licensed-therapist-david","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ibogaine-by-david-dardashti-unveils-minimalist-jungian-paradigm-for-early-trauma-appoints-licensed-therapist-david_828551.html","title":{"rendered":"Ibogaine By David Dardashti Unveils Minimalist Jungian Paradigm for Early Trauma, Appoints Licensed Therapist David"},"content":{"rendered":"
\"Ibogaine<\/a><\/div>\n

MIAMI, FL – <\/strong>Reframing the landscape of deep psychological recovery, Ibogaine By David Dardashti has officially appointed licensed therapist David Douglas as Admissions Coordinator. In a bold departure from traditional high-intervention clinical models, the facility is introducing a specialized framework focused on Jungian archetypes—specifically the “child archetype”—to decode early childhood trauma, while pioneering a minimalist therapeutic approach where the patient takes center stage in their own healing.<\/p>\n

In his expanded capacity, Douglas will steer patient intake, analyze psychological profiles prior to treatment, and offer post-treatment therapeutic support. Rather than viewing ibogaine as a standalone physical reset, Douglas’s methodology addresses the foundational subconscious trauma that frequently drives adult addiction, anxiety, and recurring behavioral loops.<\/p>\n

“True recovery requires looking directly into the mirror of the subconscious,” explains David Douglas, Licensed Therapist. “By examining patient psychology through Jungian archetypes—predominantly the child archetype—we can trace adult suffering back to original developmental wounds. My role is to help patients uncover these buried narratives during intake and offer a supportive bridge as they reconcile with their past after treatment.”<\/p>\n

Central to the facility’s approach is a radically patient-centric philosophy: minimal therapeutic interference<\/strong>. Traditional rehabilitation often relies on heavy counselor intervention, but Ibogaine By David Dardashti operates on the belief that profound, sustained transformation is inherently self-directed.<\/p>\n

Within this framework, the treatment process and the patient collaborate to perform the overwhelming majority of the restorative work. The counselor does not impose answers or force emotional outcomes; instead, the therapist serves strictly as a mediator, gently facilitating the individual’s personal relationship with their inner past.<\/p>\n

“We don’t believe in over-steering the patient’s narrative,” says founder David Dardashti. “David Douglas brings extraordinary psychological insight, but he honors the core truth of our philosophy: the therapist is merely a mediator. The real, lasting breakthrough happens when the patient steps into the driver’s seat and directly heals their own inner child.”<\/p>\n

By pairing precise archetypal evaluation with minimal clinical interference and long-term integration support, Douglas ensures patients possess both the agency and the guidance necessary to convert profound insights into permanent personal transformation.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Ibogaine By David Dardashti<\/a>
Contact Person:<\/strong> Cole Barressi
Email:<\/strong> Send Email<\/a>
Country:<\/strong> United States
Website:<\/strong> www.ibogaineclinic.com<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

MIAMI, FL – Reframing the landscape of deep psychological recovery, Ibogaine By David Dardashti has officially appointed licensed therapist David Douglas as Admissions Coordinator. In a bold departure from traditional high-intervention clinical models, the facility is introducing a specialized framework focused … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,420,411,404,416],"tags":[],"class_list":["post-828551","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Science","category-Technology","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/828551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=828551"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/828551\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=828551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=828551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=828551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}